An interventional study of Synthes TFNA and Trigen InterTAN in Fracture of Hip, sponsored by Paul E. Matuszewski. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Paul E. Matuszewski · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.
Among the 133 studies in Hip Fractures with a site in United States, this one is the 73rd largest by planned enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2025, is one of 62 with no phase, reaches primary completion later than 6 of the 30 other live ones, and was the 107th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 65+
SI-BONE, Inc. · Sites in United States
Ages 60+
University of Maryland, Baltimore · Sites in United States
Ages 60+
University of Southern California · Sites in United States, Canada, Norway and 2 more countries
Ages 60+
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 10 · Phase 4 15
First in 1980; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 64 across the 105 interventional studies, 160 across the 26 observational. Of the 84 that completed or were terminated, 36 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 133 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Paul E. Matuszewski as lead sponsor.
Paul E. Matuszewski has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
16 of the studies in Hip Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407427Yale UniversityEvaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation | 2026-12 |
| NCT04809714University of Alabama at BirminghamThe Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture | 2026-12-13 |
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT06024304Paul E. MatuszewskiInterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery | 2027-01-01 |
| NCT04937868University of California, Los AngelesDeveloping a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients | 2027-01-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 133 studies in Hip Fractures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot, patient blinded randomized trial is to develop a mechanistic understanding of gait following fixation of unstable intertrochanteric hip fractures and return to function and pain control. The guiding hypothesis that will be tested in a subsequent clinical trial is that the InterTAN when compared to standard lag-screw cephalomedullary nails will have decreased post operative pain, earlier return to symmetric weight bearing, and quicker return to pre-injury functioning levels.
Aim 1: Determine the feasibility of conducting a randomized trial assessing gait mechanics as well as outcomes following unstable intertrochanteric femur fractures treated with cephalomedullary nails. This will be achieved by performing a pilot randomized trial comparing the InterTAN versus a single-screw design cephalomedullary nail (SSCMN). Deliverable: Preliminary data to support a larger randomized trial powered on either mechanical assessments or patient reported outcomes. Feasibility of conducting comprehensive biomechanical and patient related outcome measurements in the geriatric hip fracture population.
Aim 2: Determine the pathway to return to function and symmetric weight bearing. Load bearing will be assessed through insole monitoring during their inpatient stay and 2-weeks post-op. Additionally, analysis will be performed to measure gait for hip motion, loading, strength and functional assessments at 6,12, and 26 weeks post-op. Patients will also be assessed at 1-year for reported function as well. Hypothesis: Patients in the InterTAN group will have faster return to symmetrical weight bearing/motion and earlier return to function. Deliverable: Longitudinal data assessing return to function and weight bearing in intertrochanteric femur fractures.
Aim 3: Determine if use of the InterTAN device when compared to SSCMN results in decreased pain following unstable intertrochanteric femur fractures. Patients will be enrolled in a prospective trial with standardized pain control regimen, assessing patients for pain during their hospital stay using Area Under the Curve Analysis of Visual Analogue Pain Scores at 24, 48 and 72 hours. Similarly, opioid usage in morphine milligram equivalents will be assessed. Pain will be assessed at follow-up visits 6, 12, 26, 52 weeks. Hypothesis: The InterTAN will result in decreased pain in the immediate post-operative period and in sub-acute post-operative period.
Aim 4: Determine if the use of the InterTAN device when compared to SSCMN results in decreased healthcare utilization. Participation with therapy, hospital length of stay, discharge disposition, and time-spent in rehabilitation facility will be assessed. Hypothesis: Patients in the InterTAN group will be more likely to be discharged home, participate with therapy more, have decreased length of stay in both inpatient and outpatient units. Deliverable: Data to inform the power analysis for a larger prospective clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith \& Nephew.
Device: Trigen InterTAN
Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.
Device: Synthes TFNA
Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
Change in self-reported physical function
Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire is a 53 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates less physical function.
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Change in self-reported pain
Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Questionnaire is a 56 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates increased interference due to pain.
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Change in Functional Independence Measure
The Functional Independence Measure (FIM) is a tool used to measure the level of disability as well as the change in patient status. FI is comprised of 18 items, grouped into 2 subscales - motor and cognition. Each item is scored on a 7 point ordinal scale, ranging from a score of 1 to a score of 7. The higher the score, the more independent the patient is in performing the task associated with that item.
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Change in pain assessment
Brief Pain Inventory (BPI) will be used to measure pain intensity. This is a four-item scale that measures current, worst, least, and average pain. Each of these four items are measured on a numeric scale from 0 to 10 with 0 being ''no pain'' and 10 being ''severe pain.''
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Change in weight bearing
The ground reaction forces of the injured and non injured limb will be evaluated over the course of recovery to assess when loading between limbs becomes symmetric during their physical therapy.
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Change in Visual Analog Pain Score
The visual analog pain score is a horizontal line with a scale ranging from 0 to 10 where a higher number indicates more pain.
Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.
Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 20 months is below that.
Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.